Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TargetTau-1: BMS-986446 in Early Alzheimer’s Disease
2023-504840-32-00Phase 2Authorised
- Sponsor
- Bristol Myers Squibb
- Start
- Sep 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 10
01
Overview
Phase 2, randomised, double-blind trial in Alzheimer's disease (AD) comparing BMS-986446 (PRX005) with Placebo (2 arms). Primary endpoint: Change in brain tau deposition at Week 76. Planned start Sep 2024; status: authorised.
02
Drugs
PRX005
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on 2023-504840-32-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-504840-32-00.